Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia KYN-5356, an innovative, first-in-class small molecule inhibitor of KAT-II, a key enzyme in the kynurenine pathway implicated in schizophrenia, was shown to be safe and well-tolerated in the phase 1...

Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases NAARDEN, The Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain...

Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia KYN-5356 is an innovative, first-in-class small molecule that targets KAT-II, a key enzyme in the kynurenine pathwayTopline results are expected in the second half of 2024 NAARDEN, The Netherlands,...

Kynexis Launched to Advance Precision Therapeutics for Brain Diseases - Lead Candidate KYN-5356, a First-In-Class Small Molecule KAT-II Inhibitor, Advancing Toward the Clinic for Cognitive Impairment Associated With Schizophrenia - €57 Million Series A Led by Forbion ...